Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: A new class of antimalarial therapeutics

Journal of Medicinal Chemistry

Volumn 52, Issue 14, 2009, Pages 4391-4399

  Keough, Dianne T ^a   Hocková, Dana ^b   Holý, Antonín ^b   Naesens, Lieve M J ^c   Skinner Adams, Tina S ^d   De Jersey, John ^a   Guddat, Luke W ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 (PHOSHONOMETHOXY)ETHYLGUANINE; 2 (PHOSPHONOETHOXY)ETHYLGUANINE; 2 (PHOSPHONOMETHOXY)ETHYLGUANINE ISOOCTYL ESTER; 2 (PHOSPHONOMETHOXY)ETHYLGUANINE ISOPROPYL ESTER; 2 (PHOSPHONOMETHOXY)PROPYLGUANINE; 3 FLUORO 2 (PHOSPHONOMETHOXY)PROPYLGUANINE; 3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYLGUANINE; ANTIMALARIAL AGENT; CYCLIC 3 HYDROXY (PHOSPHONOMETHOXY)PROPYLGUANINE; FUNCTIONAL GROUP; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE INHIBITOR; NUCLEOSIDE PHOSPHONIC ACID DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PURINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL CULTURE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PLASMODIUM FALCIPARUM; STRUCTURE ANALYSIS;

ANIMALS; ANTIMALARIALS; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL SURVIVAL; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; ERYTHROCYTES; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; NUCLEOSIDES; PHOSPHONIC ACIDS; PLASMODIUM FALCIPARUM; PURINONES; SUBSTRATE SPECIFICITY;

EID: 67650745021     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900267n     Document Type: Article

References (36)

1. Hay, S. I.; Guerra, C. A.; Tatem, A. J.; Noor, A. M.; Snow, R. W. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect. Dis. 2004, 4, 327-336.
2. Talisuna, A. O.; Bloland, P.; D'Alessandro, U. History, dynamics, and public health importance of malaria parasite resistance. Clin. Microbiol. Rev. 2004, 17, 235-254.
3. Ting, L.-M.; Shi, W.; Lewandowiez, A.; Singh, V.; Mwakingwe, A.; Birck, M. R.; Ringia, E. A. T.; Bench, G.; Madrid, D. C.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Schramm, V. L.; Kim, K. Targeting a novel Plasmodium recycling pathway with specific immucillins. J. Biol. Chem. 2005, 280, 9547-9554.
4. Dawson, P. A.; Gordon, R. B.; Keough, D. T.; Emmerson, B. T. Normal HPRT coding region in a male with gout due to HPRT deficiency. Mol. Genet. Metab. 2005, 85, 78-80.
5. Deo, S. S.; Tseng, W. C.; Saini, R; Coles, R. S.; Athwal, R. S. Purification and characterization of Escherichia coli xanthine-guanine phosphoribosyltransferase produced by plasmid pSV2gpt. Biochim. Biophys. Acta 1985, 839, 233-239.
6. Vos, S.; de Jersey, J.; Martin, J. L. Crystal structure of Escherichia coli xanthine-phosphoribosyltransferase. Biochemistry 1997, 36, 4125-4134.
7. Queen, S. A.; van der Jagt, D.; Reyes, P. Properties and substrate specificity of a purine phosphoribosyltransferase from the human malaria parasite Plasmodium falciparum. Mol. Biochem. Parasitol. 1982, 30, 123-134.
8. Keough, D. T.; Ng, A. L.; Winzor, D. J.; Emmerson, B. T.; de Jersey, J. Purification and characterization of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase and comparison with the human enzyme. Mol. Biochem. Parasitol. 1999, 98, 29-41.
9. Xu, Y.; Eads, J.; Sacchettini, J. C.; Grubmeyer, C. Kinetic mechanism of human hypoxanthine-guanine phosphoribosyltransferase. Biochemistry 1997, 36, 3700-3712.
10. Li, C. M.; Tyler, P. C.; Furneaux, R. H.; Kicska, G.; Xu, Y.; Grubmeyer, C.; Girvin, M. E.; Schramm, V. L. Transition state analogs as inhibitors of human and malarial hypoxanthine-guanine phosphoribosyltransferases. Nat. Struct. Biol. 1999, 6, 582-587.
11. Shi, W.; Li, C. M.; Tyler, P. C.; Furneaux, R. H.; Grubmeyer, C; Schramm, V. L.; Almo, S. C. The 2.0 Å structure of human hypoxanthine-guanine phosphoribosyltransferase with a transition-state analog inhibitor. Nat. Struct. Biol. 1999, 6, 588-593.
12. Shi, W.; Li, C. M.; Tyler, P. C.; Furneaux, R. H.; Cahill, S. M.; Girvin, M. E.; Grubmeyer, C.; Schramm, V. L.; Almo, S. C. The 2.0 Å structure of malarial purine phosphoribosyltransferase in complex with transition-state analogue inhibitor. Biochemistry 1999, 38, 9872-98780.
13. Keough, D. T.; Skinner-Adams, T.; Jones, M. K.; Ng, A. L.; Brereton, I. M.; Guddat, L. W.; de Jersey, J. Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases. J. Med. Chem. 2006, 49, 7479-7486.
14. De Clercq, E.; Holý, A. Acyclic nucleoside phosphonates: A key class of antiviral drugs. Nat. Rev. Drug Discovery 2005, 4, 928-940.
15. Smeijsters, L. J. J. W.; Franssen, F. F. J.; Naesens, L.; de Vries, E.; Holý, A.; Balzarini, J.; de Clercq, E.; Overdulve, J. P. Inhibition of the in vitro growth of Plasmodium falciparum by acyclic nucleoside phosphonates. Int. J. Antimicrob. Agents 1999, 12, 53-61.
16. Keough, D. T.; Brereton, I. M.; de Jersey, J.; Guddat, L. W. The crystal structure of free human hypoxanthine-guanine phosphoribosyltransferase reveals extensive conformational plasticity throughout the catalytic cycle. J. Mol. Biol. 2005, 351, 170-181.
17. Eads, J.; Scapin, G.; Xu, Y.; Grubmeyer, C.; Sacchettini, J. C. The crystal structure of human hypoxanthine-guanine phosphoribosyltransferase with bound GMP. Cell 1994, 78, 325-334.
18. Holý, A.; Rosenberg, I.; Dvořáková, H. Acyclic nucleotide analogs. 8. Synthesis of N-(2-(2-phosphonylethoxy) ethyl derivatives of heterocyclic bases. Collect. Czech. Chem. Commun. 1990, 55, 809-818.
19. Holý, A.; Gunter, J.; Dvořáková, H.; Masojídková, M.; Andrei, G.; Snoeck, R.; Balzarini, J.; De Clercq, E. Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base. J. Med. Chem. 1999, 42, 2064-2086.
20. Holý, A.; Dvořáková, H.; Jindřich, J.; Masojídková, M.; Buděšínský, M.; Balzarini, J.; Andrei, G.; De Clercq, E. Acyclic nucleotide analogs derived from 8-azapurines: Synthesis and antiviral activity. J. Med. Chem. 1996, 39, 4073-4088.
21. Holý, A.; Rosenberg, I.; Dvořáková, H. Synthesis of N-(2-phosphonylmethoxyethyl) derivatives of heterocyclic bases. Collect. Czech. Chem. Commun. 1989, 54, 2190-2210.
22. Holý, A. Synthesis of enantiomeric N-(3-hydroxy-2- phosphonomethoxypropyl) derivatives of purine and pyrimidine bases. Collect. Czech. Chem. Commun. 1993, 58, 649-674.
23. Holý, A.; Masojídková, M. Synthesis of enantiomeric N-(2-phosphonomethoxypropyl) derivatives of purine and pyrimidine bases. I. The stepwise approach. Collect. Czech. Chem. Commun. 1995, 60, 1390-1409.
24. Jindřich, J.; Holý, A.; Dvořáková, H. Synthesis of N-(3-fluoro-2-phosphonomethoxypropyl) (FPMP) derivatives of heterocyclic bases. Collect. Czech. Chem. Commun. 1993, 58, 1645-1667.
25. McPhillips, T. M.; McPhillips, S. E.; Chiu, H. J.; Cohen, A. E.; Deacon, A. M.; Ellis, P. J.; Garman, E.; Gonzalez, A.; Sauter, N. K.; Phizackerley, R. P.; Soltis, S. M.; Kuhn, P. Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines. J. Synchrotron Radiat. 2002, 9, 401-406.
26. Pflugrath, J. W. The finer things in X-ray diffraction data collection. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1999, 55, 1718-1725.
27. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Method Enzymol. 1997, 276, 307-326.
28. Navaza, J. AMoRe: an automated package for molecular replacement. Acta Crystallogr., Sect. A: Found. Crystallogr. 1994, 50, 157-163.
29. Elmsley, P.; Cowtan, K. Coot model-building tools for molecular graphics. Acta Crystallogr., Sect D: Biol. Crystallogr. 2004, 60, 2126-2132.
30. Collaborative Computational Project Number 4. The CCP4 Suite: Programs for Protein Crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763.
31. Potterton, E.; Briggs, P.; Turnenburg, M.; Dodson, E. A graphical user interface to the CCP4 program suite. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2003, 59, 1131-1137.
32. Hamzah, J.; Skinner-Adams, T.; Davis, T. M. In vitro antimalarial activity of retinoids and its influence on selective retinoic acid receptor antagonists. Acta Trop. 2003, 87, 345-353.
33. Giemsa, G. Eine vereinfachung und verrvolkommung meiner meth-hylenlau-eosin rfmethods zur erzielung romanowsky-nacht achen chromatinf rhung. Abseilung 1904, 32, 307-313.
34. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
35. Giacomello, A.; Salerno, C. Human hypoxanthine-guanine phosphoribosyltransferase. Steady state kinetics of the forward and reverse reactions. J. Biol. Chem. 1978, 253, 6038-6044.
36. el Kouni, M. H. Potential chemotherapeutic targets in the purine metabolism of parasites. Pharmacol. Ther. 2003, 99, 283-300.